EGFR and non-small cell lung carcinoma: In addition, anlotinib showed antitumor activity on tumor cells carrying mutations in epidermal growth factor receptor (EGFR).10, 11 Phase I clinical trial has established the safety profile of anlotinib and identified commended dose of 12 mg once daily at the 2 weeks on treatment followed by 1 week off treatment schedule.11 In phase II, as a third‐line and above treatment for patients with advanced non‐small‐cell lung cancer (NSCLC), anlotinib has got an affirmatory efficacy on patients with advanced NSCLC, in ALTER0302 double‐blind, controlled trial.12